Economic Burden of Adverse Drug Reactions and Potential for Pharmacogenomic Testing in Singaporean Adults
Applied/Translational Research
Care Process & Redesign
Singapore Healthcare Management Congress
National University Health System
SingHealth
31 December 2018
Quantify the economic burden of adverse drug reactions (ADRs) and estimate the breakeven cost for preemptive pharmacogenomic. PGx testing shows promise for reducing ADR-related costs and improving patient safety.
Year Submitted: 2018
Published Date: 31 December 2018
Tags: Care Process ＆ Redesign, Applied/Translational Research, Quality Improvement, Clinical Practice Improvement, Value Based Care, Safe Care, Operational Management, Financial Management, Quantitative Research
About this Content
Aims
Quantify the economic burden of adverse drug reactions (ADRs) and estimate the breakeven cost for preemptive pharmacogenomic (PGx) testing.
Background
ADRs significantly contribute to hospital admissions, raising healthcare costs. Preemptive PGx testing could mitigate these effects.
Methods
Conducted a survey of 1,000 hospital admissions, analyzed cost impacts, and assessed potential savings from PGx testing.
Results
ADR-related admissions cost S$788,298; estimated potential annual savings of S$158 per patient using PGx testing.
Conclusion
PGx testing shows promise for reducing ADR-related costs and improving patient safety.
Lessons Learnt
ADR prevention through PGx requires multidisciplinary collaboration and economic feasibility studies.
Additional Information
Singapore Healthcare Management 2018 – Highlighted Research on Economic Burden and Pharmacogenomics.
Keywords
Pharmacogenomics, ADR, Economic Burden, Safety, Hospitalization Costs, Genetic Testing.
Innovators' Details
Innovators' Details
Healthcare Cluster(s) | SingHealth, National University Health System |
Organization(s) Involved | Singapore Health Services, Singapore General Hospital, Agency for Science Technology and Research, University of British Columbia, National University of Singapore |
Platform(s) | Singapore Healthcare Management Congress |
Healthcare Professional Group(s) | Pharmacy |
Applicable Specialty or Discipline | Pharmacology, Clinical Research |
Project Lead(s) | Chan Sze Ling |
Project Member(s) | Ng Hong Yen |
Connect with this contributor!
Chan Sze Ling - chan.sze.ling@singhealth.com.sg
Project Attachment
SHM_FN004_SingHealth_Economic_Burden_of_Adverse_Drug_Reactions_combine.pdf